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Abstract
TWIST and adenomatosis polyposis coli (APC) are critical signaling factors in normal bone development. In previous studies examining
a homogeneously treated cohort of pediatric osteosarcoma patients, we reported the frequent and concurrent loss of both TWIST and
APC genes. On these bases, we created a related animal model to further explore the oncogenic cooperation between these two
genes. We performed intercrosses between twist-null/+ and Apc1638N/+ mice and studied their progeny. The Apc1638N/+;twist-
null/+mice developed bone abnormalities observed bymacroscopic skeletal analyses and in vivo imaging. Complementary histologic,
cellular, andmolecular analyses were used to characterize the identified bone tumors, including cell culture and immunofluorescence
of bone differentiation markers. Spontaneous localized malignant bone tumors were frequently identified in Apc1638N/+;twist-null/+
mice by in vivo imaging evaluation and histologic analyses. These tumors possessed several features similar to those observed in
human localized osteosarcomas. In particular, the murine tumors presented with fibroblastic, chondroblastic, and osteoblastic osteo-
sarcoma histologies, as well as mixtures of these subtypes. In addition, cellular analyses and bone differentiationmarkers detected by
immunofluorescence on tumor sections reproduced most murine and human osteosarcoma characteristics. For example, the early
bone differentiation marker Runx2, interacting physically with hypophosphorylated pRb, was undetectable in these murine osteo-
sarcomas, whereas phosphorylated retinoblastoma was abundant in the osteoblastic and chondroblastic tumor subtypes. These
characteristics, similar to those observed in human osteosarcomas, indicated that our animal model may be a powerful tool
to further understand the development of localized osteosarcoma.
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Introduction
Misexpressions of critical developmental and signaling factors seem to
be decisive events in oncogenesis. In the case of osteosarcomas, our
laboratory has demonstrated that several genes involved in bone devel-
opment are potential oncogenes, as well as being useful prognostic
markers of the clinical outcomes [1–3]. Among the genes important
for bone development, we have shown that the concurrent loss of both
TWIST and adenomatosis polyposis coli (APC ) genes occurs in osteo-
sarcomas of human patients with a very poor prognosis [3]. On the
basis of these data, we decided to create an animal model with simul-
taneous loss of Twist and Apc and to demonstrate and further examine
the oncogenic cooperation between these genes. We hypothesized that
spontaneous osteosarcoma development would occur in the Apc;twist
heterozygous progeny from an intercross between twist-null and Apc
mutant mice.
Currently, the development of animal models is required to fully
understand humanmalignant processes. To the best of our knowledge,
only few murine models of osteosarcoma have been established, in-
cluding genetically engineered models [4–6], irradiated mice [7], or
murine and human osteosarcoma cell lines injected subcutaneously or
orthotopically into nude mice [8,9]. Most of the genes implicated in
these animal models play a role in the cell response to cell division signals,
including transgenic mice overexpressing cFos [4,5] or p53-deficient
mice [6,7,10,11]. Usually, the gene deregulations are induced artificially
and/or ectopically in bones. In contrast, our target genes are generally
described in differentiation pathways and are congenitally under-
expressed in our model.
Twist haploinsufficiency was shown to upset bone tissue in both
mice and humans [12,13] and was linked to a syndromic craniosyn-
ostosis diagnosis: the Saethre-Chotzen syndrome [14,15]. However,
neither bone tumors nor malignancies have been reported in human
or murine populations with the mutated TWIST gene. In the litera-
ture, high expression of TWIST has been described in several cancers
[16–19] and has been associated with the initial phase of metastatic
progression [20]. On contrast, in our homogeneous cohort of osteo-
sarcoma patients [21], the TWIST gene was frequently deleted in the
tumors at diagnosis, and its haploinsufficiency was significantly corre-
lated with a poorer patient outcome and the APC gene loss of hetero-
zygosity (LOH) [3].
The Apc/β-catenin/Gsk complex is the cytoplasmic transducer of
the Wnt signaling pathway [22,23]. APC mutations lead to β-catenin
accumulation and constitutive activation of Wnt-signaling targets, in
the absence of Wnt inducer [24,25]. APC LOH is often associated
with somatic mutations in the other allele, as it has been described in
colon cancers [22]. However, no somatic mutations in the other APC
allele were found in our osteosarcoma cohort, only gene deletions
were observed [3].
Both Twist gene and Apc/β-catenin/Gsk complex positively regu-
late Runx2, common target of the two pathways [26,27]. Runx2 ex-
pression is reduced in cultured osteoblasts by Twist inactivation [28],
whereas its repression is a consequence of the misexpression of Apc
[27]. Runx2 plays a prominent role in committing mesenchymal
cells toward a bone cell lineage and interacts with the hypophosphory-
lated form of phosphorylated retinoblastoma (pRb) to inhibit cell
division [26].
In the present study, we validate our hypothesis that combined
TWIST and APC gene dysfunctions cooperate in the development of
osteosarcoma. For this purpose, we used twist-null [14] and Apc1638N
[29] heterozygous mice as our experimental tools. The twist-null
mouse is widely well known as a reference in the study of Twist gene.
The Apcmutant mouse is known to display a relatively mild intestinal
cancer phenotype and to live longer than other Apc mutant mice, rea-
son why this animal strain was selected [30–32]. The Apc1638N/+;
twist-null/+ mice developed spontaneously malignant bone tumors,
which were characterized as osteosarcomas by in vivo imaging and his-
tology. At the molecular level, we further analyze these tumors by de-
tecting the presence of bone differentiation markers in tumor tissue
sections, genotyping the tumors, performing in vitro and in vivo assays.
Mechanistically, the combined Apc;twist deficit results in the decreased
expression of Runx2, independently from hypophosphorylated pRb
expression. With all these macroscopic and molecular characteristics,
our mouse model seems to confirm the synergistic effect of Twist haplo-
insufficiency andWnt/β-catenin/Apc deficiency in the malignant process
of osteosarcomas.
Materials and Methods
Mouse Husbandry, Genotyping, and Skeleton Preparations
All animal experiments were performed according to French Animal
Regulations. The animals were generated by crossing twist-null hetero-
zygotes (on C57BL/6J and CD1 pure backgrounds for >20 generations)
withApc1638Nheterozygotes (129Sv background). Backcrosses and in-
tercrosses were performed to develop congenic and mixed background
animals and to discriminate the phenotype because of the two stud-
ied mutant genes from the consequences of genetic modifiers, which
might be present in the backgrounds. Mice were systematically geno-
typed by conventional polymerase chain reaction–based procedures using
Eppendorf Mastercycler ep gradients (Harlow Scientific, Arlington,
MA). Twist gene genotyping was done with primers previously de-
scribed [14], whereas Apc genotyping was performed with primers pro-
vided by Dr R. Fodde. The Apc genotyping was also used to analyze
tumor tissues. Same-sex littermates of the four genotypes were raised
together until they were simultaneously analyzed. P0 up to 22-month-
old littermate animals were collected at several generations in back-
crosses. Thus, the phenotypes were studied at different levels of strain
purity and background mixes (F1, F4, F8, F10, etc). To detect whether
any maternal or paternal inheritance would modify the severity of the
phenotype in progeny, we crossed males bearing the Twistmutant allele
with mutant Apc females and reverse.
After animal sacrifice, skeletons were prepared as previously de-
scribed [13].
In Vivo Imaging Evaluation of Living Mice
A cohort of living mice were analyzed by in vivo exploration. X-ray
micro–computed tomography (X-ray μCT) and micro–single-photon
emission computed tomography (μSPECT) were performed using a
dual-modality system, the eXplore speCZT Vision 120 (GE Health-
care, London, Ontario, Canada). After anesthesia of the mice, using iso-
flurane in air (5% at induction then 1.5% to 2% during examination),
0.1 to 0.25ml of Osteocis (HMDP 99mTc 74-111MBq; CIS Bio Inter-
national, Gif-sur-Yvette, France) were injected into the tail vein. A 1-hour
duration was maintained between the time of injection and the μSPECT
acquisitions, which were done using a cylindrical slit collimator (eight
slits) or a pinhole collimator (seven pinholes). Forty-five angle posi-
tions (each lasting 20 seconds) were taken for a total acquisition time
of 15 minutes. Reconstructions (energy window, 130-150 keV) were
done using a three-dimensional OSEM algorithm, with reconstructed
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voxels of 550 × 550 × 2460μm3with the slit collimator and 330 × 330 ×
330 μm3 with the pinhole collimator. The μCTwas performed using
220 projections with an angle increment of 0.877 degrees (Parkermode)
and one average frame per projection (70.0 kV, 32 mA, and exposition
time of 16 milliseconds). Reconstructions were done using a Feldkamp
algorithm giving voxels of 100 × 100 × 100 μm3. In case of abnormal
structures, seen in the images of the firstμCTacquisition, a secondμCT
acquisition was performed with a smaller voxel size (50 × 50 × 50 μm3).
For comparison, μCT and μSPECT images were superimposed using
MicroView (GE Healthcare).
Cell Cultures
Cells from two osteosarcomas of two Apc1638N/+;twist-null/+ mice
and from normal bones of twist-null/+, Apc1638N/+ and Apc1638N/
+;twist-null/+ mice (2-mm3 samples) were cultured in medium con-
taining RPMI, Ammiomax II, 10% standard fetal calf serum, and 1%
glutamine. For the agarose gel colony formation assay, two layers of
0.5% agarose (Bio-Rad, Paris, France) were used. Colony formation
and expansion were enumerated after a 2-week multiplication period.
Murine Tumor Xenografting
Male athymic nudemice (6-week-old animals) were purchased from
Charles River Laboratories (Chatillon-Sur-Chalaronne, France) and
were maintained under pathogen-free conditions. One of the costal
tumors isolated from an Apc1638N/+;twist-null/+ mouse and one cul-
tured tumor lysate (30 × 106 cells) were used separately for subcutaneous
injection into these immunocompromised mice. The subcutaneous
tumors were measured three times a week.
Karyotyping
Standardized mouse karyotyping was performed, and computer-
assisted karyotyping was used to compare bone tumor and control
mouse cells.
Histology
Soft tissue and bone tumors isolated after in vivo imaging were fixed
in 4% formaldehyde. The bone specimens were decalcified and paraffin-
embedded for histologic analyses. All tumors were stained with hema-
toxylin and eosin (Sigma, St. Quentin, France). Serial sections (5 μm)
were obtained from eight murine osteosarcomas, which were chosen
because of their large size, allowing to perform all protein analyses. These
eight bone tumors were isolated from eight different Apc1638N/+;twist-
null/+ mice.
Analyses of Protein Expression by Immunofluorescence
Standard protocols were used to deparaffinize the mouse tumor
serial sections. Slides were saturated with 1% bovine serum albumin in
1× phosphate-buffered saline (PBS) and incubated with antibody for
2 hours at room temperature. Rabbit anti–β-catenin (SC199), anti-
RankL (SC9073) and anti-Runx2 (SC10758), goat anti-osteonectin
(SC13326), anti-Col1A1 (SC25974), anti-osteocalcin (SC18322), and
anti-pRb (SC16671) (Santa Cruz Biotechnology, Heidelberg, Germany)
were incubated on tissue sections at dilutions ranging from 1:100 to
1:800. After washing with PBS to remove background, 1:100 or 1:200
dilutions of Alexa 488– and/or Alexa 594–coupled antirabbit or antigoat
secondary antibodies (Invitrogen, Cergy Pontoise, France) were used for
immunodetection. Incubations with 4′,6′-diamidino-2-phenylindole
(Sigma) were used to detect the nuclei. Detections of pRb and Runx2
were done after antigen retrieval and 2.5% Triton permeabilization of
the tissue sections. Control slides were obtained by replacing the pri-
mary antibodies with PBS.
Results
Generation of Apc1638N/+;twist-null/+ Mice
Mice combining haploinsufficiency of Twist and heterozygous for
theApc1638Nallele, referred hereafter as theApc1638N/+;twist-null/+
mice, are the progeny of an intercross between twist-null andApc1638N
heterozygotes. Littermates from more than 90 crosses were genotyped,
and no developmental lethality was observed as almost equivalent
numbers of living pups for each of the four genotypes. From a total
number of 530 animals, 29% (154/530) were wild-type (WT), 25%
(133/530) were twist-null/+, 26% (137/530) were Apc1638N/+, and
20% (106/530) were Apc1638N/+;twist-null/+. Among them, 253 fe-
males and 277 males were numbered. The intercrosses were initially pro-
duced using pure CD1 and C57BL/6J backgrounds for twist-null/+
animals and a 129Sv background for Apc1638N/+. Backcrosses and
intercrosses were regularly performed in subsequent generations. Of
the first 530 animals, we observed 182 animals with CD1 background,
175 mice presenting C57BL/6J background, and 173 mice with
129Sv background.
Apc1638N/+;twist-null/+ Mice Have Soft Tissue and Bone
Abnormalities Similar to Those of the Apc1638N/+ and
Twist-null /+ Heterozygotes
Apc1638N/+ mice have been reported to develop intestinal cancers
and extraintestinal manifestations [29,30,32]. Macroscopically, soft tis-
sue tumors were approximately two times as frequent in Apc1638N/
+;twist-null/+ mice than in Apc1638N/+ mice. No soft tissue tumors
were observed in any of the twist-null/+ animals. Histology classified
these soft tissue tumors as desmoid and keratinoid tumors. No malig-
nant tumors were observed in the intestines in any of the mice from all
four genotypes. Of all animals, 13 spontaneous adenomas were found
in 73 examined Apc1638N/+;twist-null/+ animals and 21 were found
in 112 examined Apc1638N/+ mice.
In terms of the bones, we analyzed the complete skeletons of the 73
of 106 Apc1638N/+;twist-null/+ mice that were, first, generated. In full
agreement with our previous unpublished studies of the twist haplo-
insufficient phenotype and, beside secondary bone anomalies reported
in previous publications [13,15], the major specific bone features were
a complete bilateral or unilateral coronal suture fusion and bilateral or
unilateral posterior hallux duplications, occurring as a fully penetrant
phenotype in C57BL/6J background. These observations were present
in the Apc1638N/+;twist-null/+ animals, as well as for the twist-null/+
mice with this background, whereas on animals with a CD1 back-
ground, no duplication of the halluces was observed, and coronal sutures
were only partially fused.
Bone Tumors Are Limited to the Apc1638N/
+;twist-null /+ Mice
In addition to the bone phenotype specific of the twist-null/+
heterozygotes, 14 (19.2%) of the 73 analyzed Apc1638N/+;twist-
null/+ skeletons presented bone tumors, which were mostly found
in the cephalic region (Figure 1). The earliest tumors were seen in
the 5-month-old Apc1638N/+;twist-null/+ mice (Table 1). They were
frequently associated with one or two other bone tumors at other bone
locations: in more than 70% (10mice), an average of two concomitant
tumors was observed. On the basis of these initial results, we limited
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our analyses to the cephalic region, where the tumors were predomi-
nantly seen. We generated 92 new Apc1638N/+;twist-null/+ animals,
aged between 5 and 22 months, when they were killed. In this popula-
tion, tumor development occurred in 30 (32.6%) of 92 cephalic struc-
tures. The size of the tumors did not correlate with the age of the animal
at the time of examination. In addition, there were no differences in the
penetrance of the bone tumors between sexes and backgrounds. No
bone tumors were seen in the WT or the twist-null/+ mice. Of the
112 initial Apc1638N/+ animals, 3 presented a bone outgrowth, histo-
logically similar to osteomas.
The skeleton analyses allowed us to estimate the penetrance of
bone tumors on a large population. To go further, an in vivo imaging
evaluation was performed in a smaller cohort of living animals be-
cause of its complexity.
In Vivo Imaging and Histologic Analyses Confirm the Murine
Bone Tumors as Osteosarcomas
To localize precisely the tumors and to obtain subsequently tumor
tissues, a small cohort of mice were newly generated. Among them,
22 Apc1638N/+;twist-null/+ mice and 22 control animals, pooling
Apc1638N, twist-null, and WTmice, were selected based on age (be-
tween 10 and 18months). In the Apc1638N/+murine population, the
selection was also based on the presence of multiple soft tissue tumors.
All animals were analyzed by X-ray μCT and μSPECT. After animal
sacrifice, each tumor, which was diagnosed by in vivo imaging, was
dissected and fixed for histologic analyses. Bone tumors were detected
by X-ray μCT in 15 (68.2%) of the 22 Apc1638N/+;twist-null/+ mice
(Table 1). Among the 15 mice with bone tumors, 6 were injected with
an osteocis tracer, whose strong uptake revealed an increased osteoblas-
tic activity, witness of the malignant component. Lesions were present
at all bone sites, including head, trunk, and appendages (Figure 2, A,
C , D, E , and F ).
In the cephalic region, tumors had an osteolytic aspect (Figure 2,
A-1, A-3, and B-1), which was linked to a highly active tracer fixation
(Figure 2, A-2 and B-2), or a dense component (Figure 2, C -1–3).
Histologically, the osteolytic lesions were characterized as fibroblastic
osteosarcomas (Figure 2, A-4 and B-4 ). In Figure 2B-1, the osteolytic
bone tumor was presenting calcifications in the soft tissue extension,
witness of an osteoblastic subtype at histologic diagnosis (Figure 2B-3).
In Figure 2C-4, the dense tumor presented no tracer fixation and re-
vealed a chondroblastic osteosarcoma. Two animals were followed by
μCT at an interval of 3 months, and the volume of the tumors was
measured by segmentation. In one animal, the two tumors increased
by 88% and 93%, respectively (Figure 2, C-1 and C-2). In the second
mouse, the tumor grew by 66%. On the trunk, tumors were dense
and located on costal segments (Figure 2D), where the histologies con-
firmed chondroblastic osteosarcomas. In 2 of 15 tumor-positive mice,
the bone lesions were located in the forearm. One was having an os-
teolytic aspect and was histologically characterized as an osteoblastic
osteosarcoma (Figure 2E ). The second one was characterized by a
dense aspect with a high radioactive uptake and was defined as a chon-
droblastic subtype (Figure 2F ).
Of the 15 animals that presented with a positive μCT, 7 had two con-
comitant bone tumors and 3 had three concomitant osteosarcomas. The
bone tumors were predominantly dense lesions when localized to flat
bones, one third had an osteolytic μCT aspect, and occasionally, both
Figure 1.Malignant abnormalities observed in skeletal preparations from Apc1638N/+;twist-null/+ mice. (A) Upper side view of the skull
(0.6×) from a 9-month-old female and focus on a tumor located at the junction of the external and orbital surface of the right frontal bone
(insert at 1.2×). (B) Upper side view of the mandible from a 5-month-old mouse (0.75×) and focus on the extraosseous extension on the
lateral side of the right mandible (insert at 1.5×). (C) Lower side view of the mandible from a 5-month-old mouse (0.75×) and focus on the
osteolytic tumor located on the lower side of the left mandible (insert at 1.5×).
Table 1. Numerical Characteristics of Animals Presenting Bone Tumors (Age and Background in Each Studied Group).
Apc1638N/+;twist-null/+ Mice Animal Number Presenting
Bone Tumors
Animal Number Presenting Bone Tumors by Age Animal Number Presenting Bone Tumors by
Background
5-9 mo 10-15 mo 16-22 mo CD1 C57BL/6J 129Sv
73 skeletons 14 6 3 6 6 4 4
92 cephalic regions 30 6 12 12 9 13 8
22 living animal (in vivo imaging) 15 0 7 8 5 4 6
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Figure 2. In vivo imaging evaluation and histologic analyses of osteosarcomas in Apc1638N/+;twist-null/+ mice. (A) Frontal μCT (A1),
μSPECT (A2), and three-dimensional (3D) reconstruction (A3) images of the mandibles from a 14-month-old mouse reveal an osteolytic
tumor on the rightmandible (arrow onA3)with an active radioactivity uptake (arrow onA2). The histologic analysis (A4) shows a fibroblastic
osteosarcoma (fibrob). (B) Frontal μCT (B1) and μSPECT (B2) analyses reveal an invasive tumor on the occipital bone (arrow on B2). Within
this bulky tumor, the most active region is the peripheral area in red. The histology emphasizes the mixed nature of the tumor with both
osteoblastic (B3, osteob) and fibroblastic (B4, fibrob) subtypes. (C) Frontal μCT (C1) and three-dimensional reconstruction (C3) analyses of
twobone tumors on the leftmandible andon the right parietal bone (arrowsonC1, C2andC3). Theanalysis of the tumors taken3months later
shows an increase in the volume of the tumors (C2). Histology (C4) illustrates that this tumor is a chondroblastic osteosarcoma (chondrob).
(D) The μCT analysis (D1) and three-dimensional reconstruction (D2) from an Apc1638N/+;twist-null/+ mouse reveal dense tumors on the
fifth left and seventh right ribs (arrows). μCT (D3) and μSPECT (D4) images from anotherApc1638N/+;twist-null/+mouse reveal a lesion at
the sternocostal junction on the sixth left rib (arrow on D3) with a high osteoblastic activity in the soft tissue extension on the dorsal region
of this lesion (D4 and focus insert on D4). (E) μCT image of a bulky osteolytic tumor on the right forearm (E1) and three-dimensional recon-
struction (E2) allow an estimate of its soft tissue extension. The histologic analysis (E3,×10; E4,×40) shows an osteoblastic osteosarcoma
(osteob). (F) The μCT and the μSPECT analyses of another Apc1638N/+;twist-null/+mouse show a dense bone tumor on the right ulna (F1)
with a high radioactive uptake (F2) and its three-dimensional reconstruction (F3). Histologic analyses reveal that this lesion is a chondro-
blastic osteosarcoma (chondrob) (F4, ×10; F5, ×40). The bars on histologic slides represent 40 μm.
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imaging presentations were present. The bone tracer uptake was present
in the dense and in the osteolytic processes (Figure 2A-2, B-2, andD-4).
Two tumors had soft tissue extensions (Figure 2, B-2 and D-4). Histo-
logically, all bone tumors were typically characterized by the presence of
chondroblastic, fibroblastic, and/or osteoblastic cells and an osteoid
component. The lungs were completely normal as determined by our
μCTresolution.No tumors were observed in the 22 controlmice, which
were evaluated in parallel.
Complementary In Vivo and In Vitro Experiments Assess
the Malignant Features of These Murine Osteosarcomas
Cells from two different bulky tumors were cultured because of
availability of material. Although these tumor cells grew slowly, they
had immortalized cell properties, as they continued to grow and divide
indefinitely in vitro. In contrast, cells from the normal bone of the same
mouse and from control mice (WT, Apc1638N/+, and twist-null/+)
did not grow. The osteosarcoma cells of both tumors possessed elon-
gated stellate cytoplasmic processes (Figure 3A) until they reached con-
fluence, as previously described in human osteosarcoma cell lines [33].
A standard soft-agar colony formation assay also confirmed the malig-
nant properties of these tumor cells, as well as the tumor xenografts. In
fact, tumors at the sites of tumor cell injection grew during a period of
3 months, and histology showed similar features to those described for
the murine primary osteosarcomas. Because human osteosarcomas have
a highly rearranged karyotype, we also karyotyped the cultured murine
tumor cells. However, the karyotype of these murine tumor cells ap-
peared normal (Figure 3B). In parallel, Apc allele genotyping on the ge-
nomicDNA isolated from normal bones and eightmurine bone tumors
was performed. It revealed that the tumor cells had lost the wild-type
Apc allele in two murine osteosarcomas (T1 and T2 in Figure 3C ).
Concomitant Decreased Expression of Twist and Deregulation of
Apc/β-Catenin Seem to Alter pRb/Runx2 Cooperation
Next, we wanted to understand the mechanism underlying the dys-
function of our two target genes, Twist and Apc. To detect the presence
of discriminating markers, we performed immunofluorescence on se-
rial sections from eight paraffin-embedded osteosarcomas prepared
from eight Apc1638N/+;twist-null/+ mice. We analyzed the Wnt sig-
naling pathway, in which Apc and β-catenin are involved, bone cell lin-
eage differentiation markers (collagen 1, osteonectin, osteocalcin, and
Runx2), and pRb, interacting with Runx2.
The data obtained from tumor T38 (a chondroblastic osteosar-
coma) and from tumor T45 (a fibroblastic osteosarcoma) are shown
in Figure 4, A and B, respectively. Phase-contrast images at the extreme
left illustrate the morphologic differences between the healthy bone
and the T38 chondroblastic osteosarcoma and show the aspect of
T45 fibroblastic tumor. β-Catenin staining was nuclear in seven murine
osteosarcomas (as in the T38; Figure 4A), whereas it was located in the
nucleocytoplasmic area of the tumor cells from T45 (Figure 4B). Other
bone differentiation markers were analyzed, including collagen1 (a
marker of poorly differentiated osteoblasts), osteonectin (an early-stage
osteoprogenitor marker), and osteocalcin (a marker of mature osteo-
blasts). In the T38 osteosarcoma cells, collagen1 and osteonectin were
mostly nuclear, whereas osteocalcin staining was detected in the healthy
bone and at the border betweenmalignant osteoblasts and themalignant
osteoid matrix (Figure 4A). Immunofluorescence analyses of the T45
Figure 3. Cell culture, karyotype, and LOH analyses of the murine osteosarcomas. (A) Cultured cells from two different murine osteosar-
comas (A1 and A2) presented elongated stellate cytoplasmic processes. (B) A normal tumor karyotype is observed in the murine osteo-
sarcoma of anApc1638N/+;twist-null/+mouse. (C)Apc genotyping shows reversed balance ofmutant andwild-type bands in the controls
(c1 and c2) and the tumor (T1, T2, and T3) specimens. In T1 and T2, the mutant Apc allele is predominant and revealed an Apc loss of
heterozygosity in these tumor cells ofApc1638N/+;twist-null/+mice. The c1 and c2 specimens are normal boneDNA from the samemice.
The + sample is a Apc1638N/+ bone tissue DNA, whereas m1 DNA was extracted from a Apc1638N/+;twist-null/+ mouse without any
osteosarcoma development. M represents the size markers used for the electrophoresis.
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fibroblastic tumor revealed sparse collagen1 staining in the nuclei, osteo-
nectin staining in both nuclear and cytoplasmic compartments, and no
detection of osteocalcin, which was only observed in the healthy bone
(Figure 4B, right side).
We also investigated the presence of Runx2, which is a common
target of activated β-catenin and Twist. Our attempts to detect Runx2
were negative in seven of eight tumors (data not shown). In only one
tumor, comprising a mix of osteoblastic and fibroblastic osteosarcoma
Figure 4.Molecular signature ofmurine osteosarcomas combiningApc and twist haploinsufficiencies. (A) On the upper row, phase-contrast
imaging (at the extreme left) and immunofluorescence staining of markers were performed on sections from a dense chrondroblastic osteo-
sarcoma in the mouse named 38 (T38). Immunofluorescent detection of β-catenin is indicated by the red signaling located mainly within the
T38 nuclei. Beside this figure, the collagen1 staining, which is labeled in green, is observed in the nuclei of tumor cells but also as parallel
sheets in the healthy bone. Osteonectin, labeled in green on the fourth figure of the row A, is localizedwithin the nuclei of T38 cells, whereas
osteocalcin (at the extreme right of row A) is strongly green-labeled in the healthy part of the section (figure at the top and at the extreme right
of row A) and at the border between malignant osteoblasts and the malignant osteoid matrix of T38 tumor (figure below and at the extreme
right of rowA). (B)On the second row, anosteolytic tumor (T45, a fibroblastic osteosarcoma frommousenamed45) is shown. As in rowA, the
phase-contrast image of rowB is at the extreme left, followed by the immunofluorescence staining. The detection ofβ-catenin, labeled in red,
ismainly located in the nuclei and the cytoplasmsofT45 cells (second imageof rowB),whereas collagen1staining in green is only observed in
the nuclei of tumor cells (third image of row B). The fourth image represents the osteonectin green immunofluorescence, localized in the
nucleocytoplasm compartment of T45 cells, whereas osteocalcin, labeled also in green, is undetectable in T45 tumor cells. An osteocalcin
staining is present in the healthy bone section of T45 section. For panels A and B, DAPI, which labels the DNA, is indicated by the blue signal
and is superimposedon the greenor the red signals. (C) The detection of pRb, labeled usually in red,was performed in a chondroblastic (at the
extreme left), in an osteoblastic (in themiddle) and in a fibroblastic (at the extreme right) murine osteosarcoma. Phase-contrast images of the
tumors are shownon the top of rowC.DAPI, which stains the DNA, is indicated by the blue signal and is superimposed on the red pRb signal.
In the chondroblastic osteosarcoma subtype, only a weak, diffuse nuclear signal of phosphorylated pRb is detected, whereas in the osteo-
blastic osteosarcoma, an accumulation of phosphorylated pRb is present in both nuclear and cytoplasmic compartments. No expression of
pRb is observed in the fibroblastic subtype. The bars represent 40 μm on the different figures.
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cells, a weak Runx2 staining in the tumor nuclei was observed. Runx2
is known also to physically interact with the hypophosphorylated form
of pRb [26,34], which has been implicated in osteoblast differentia-
tion in human and murine osteosarcomas [1,6,7]. In Figure 4C , the
phase-contrast images show the three different histologic subtypes of
osteosarcomas on the upper row and the corresponding red signal of
phosphorylated pRb superimposed on 4′,6′-diamidino-2-phenylindole
staining on the lower row. In the murine chondroblastic osteosarcoma,
only a weak, diffuse nuclear signal of phosphorylated pRb (Figure 4C ,
left) was detected, whereas in the osteoblastic form, an accumulation of
phosphorylated pRb was observed in both nuclear and cytoplasmic
compartments (Figure 4C , middle). In the fibroblastic osteosarcoma,
no detectable phosphorylated pRb was showed (Figure 4C , right).
Discussion
Here we report a mouse model, which develops spontaneously osteo-
sarcomas without necessity of any inducing treatment. In fact, our
model develops osteosarcomas as a consequence of simultaneous and
congenitally haplodeficiencies of the signaling factors Twist and Apc.
The Apc1638N/+;twist-null/+ Mice Recapitulate Features of
Each Parent and Also Develop Spontaneous Osteosarcomas
Apc1638N/+;twist-null/+ mice developed the same nonmalignant
soft tissue tumors thanApc1638N/+mice [29–31], as well as bone dys-
morphic features specific of the twist-null/+ mutant [13–15].
In addition, osteosarcomas were particularly observed in the rostral
region, and they are probably reminiscent of the predominant cephalic
dysmorphologies previously described in twist-null/+ mice [13,14,35]
and of the previously published murine osteosarcoma models [4–7].
Tumor penetrance in Apc1638N/+;twist-null/+ mice (19.2%-32.6%
as determined by skeleton observations and 68.2% by in vivo imaging)
is significantly higher than those described for spontaneous malignant
bone tumors in various other inbred and hybrid mice (range from
0.3% to 7%) [36,37]. The frequency of osteosarcoma development in
the Apc1638N/+;twist-null/+ mice points toward a synergy between the
combined functional deficits of Twist and Apc. Statistical differences in
tumor frequency between the skeletal observations and in vivo imaging
evaluation may be linked to the selection of the animals: the mice, im-
aged in vivo, were an older group of mice, and they also presented with
more soft tissue tumors. The concurrent haploinsufficiencies at Twist
and Apc seem to be genetic conditions, which favor the apparition of
osteosarcomas at a relatively high frequency, but they seem not to be
sufficient conditions, as every Apc1638N/+;twist-null/+ mice do not
develop osteosarcomas.
At the time of examination, no lung metastases were detected, al-
though human osteosarcomas are reported to be frequently a metastatic
disease [38]. However, the μCTresolution used in the present study is
not able to detect microscopic lung metastases. In addition to species-
specific differences between humans and mice, one hypothesis is that
abnormalities at Twist plus Apc would represent the initial genetic con-
ditions that might favor the initiation of osteosarcoma but is not suf-
ficient to allow progression toward a metastatic lung disease.
Molecular Alterations of Our Murine Tumors Resemble
to Those of Human Osteosarcomas
The data on protein expression and cell culture characteristics are
typical of those described in human osteosarcoma cell lines [8]: all chon-
droid and immature osteoblast markers (collagen1, osteocalcin, and os-
teonectin) are present in the chondroblastic subtype and are modulated
differently in the fibroblastic subtype. These data are supported by the
fact that fibroblastic osteosarcoma cells would present fewer late osteo-
blastic differentiation markers, as in the human disease [39–41]. Fur-
thermore, β-catenin localization resembles to what has been described
in human colon cancer [42], when Apc is deleted, and confirms the con-
stant role of the Apc/β-catenin pathway in our model.
In addition, the absence of Runx2 detection in our murine tumors
was consistent with the nuclear location of β-catenin and the decrease
in Twist expression [26,34,43]. This Runx2 down-regulation was sim-
ilar to the published results in human localized osteosarcomas, where
they confirmed that normal Runx2 function is incompatible with the
osteoblast malignant transformation [34]. Furthermore, a correlation
between high Runx2 re-expression and the metastatic disease might
explain the absence of metastatic disease in our model [44]. In normal
osteoblasts, Runx2 physically interacts with the hypophosphorylated
form of pRb [34]. In our murine osteosarcomas, phosphorylated
pRb expression was present in the chondroblastic and osteoblastic sub-
types, explaining their high mitotic activity. In contrast, no phosphor-
ylated pRb was detected in murine fibroblastic osteosarcoma. RB
inconstant role was also demonstrated in our cohort of patients with
osteosarcoma, concomitantly lacking APC and TWIST genes [1]. In
the Apc1638N/+;twist-null/+ mice, osteosarcoma development might
be linked to the concomitant and predominant roles of Apc and Twist
deregulation on Runx2 expression, without an absolute requirement
of phosphorylated pRb.
Could the Apc1638N/+;twist-null/+ Mouse Be a Good
Osteosarcoma Mouse Model to Study the Human
Localized Disease?
Most of the bone tumors observed in our mouse model clearly re-
produced the imaging characteristics of human osteosarcomas. How-
ever, a large number of predominantly dense images could be seen in
our murine osteosarcomas, as it is frequently the case in craniofacial hu-
man osteosarcomas [41,45]. This location is not common in humans,
but it has been observed in other mouse models, where osteosarcomas
are mostly localized to the skull. Additional human osteosarcoma fea-
tures, shown in our model, include the appearance of the three typical
histologic subtypes (osteoblastic, fibroblastic, and chondroblastic), as
well as a mix of the three subtypes. The observed histologic subtypes
are linked to the tumor locations, as in the human disease [45–47].
So, the bone tumors in our Apc1638N/+;twist-null/+ mice, which are
primarily located in the head and the jaw, are predominantly diagnosed
as chondroblastic osteosarcomas. Furthermore, in vivo imaging evalua-
tion was also partially correlated, as in human osteosarcomas, to these
histologic differences. In fact, chondroblastic tumors mostly presented a
dense radiologic aspect (examples in Figure 2, C and F ), whereas the
osteolytic aspect wasmostly linked to the osteoblastic and/or fibroblastic
histologic components (examples in Figure 2, B and E).
At the molecular level, the observed Apc LOH in the murine tumors
underlined the presence of probable discrete genomic malignant
molecular features acquired in these cells and was concordant with
the APC LOH observed in the human osteosarcomas [3]. As a normal
karyotype is observed, the detected Apc LOH suggests that only small
alterations might be sufficient for osteosarcoma formation in our model
but not for its progression as a lung metastatic disease. It is then possible
that major chromosomal rearrangements and lung metastases will only
appear at a later step of tumor progression as a consequence of the dys-
function of an additional gene.
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In conclusion, our mouse model seems to confirm the combined
role of Twist and Apc genes in the development of murine malignant
osteoblasts and will provide new opportunities to understand further
human osteosarcomas.
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